UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000015681
Receipt number R000018227
Scientific Title Delirium prevention and prediction,Part 2
Date of disclosure of the study information 2015/02/28
Last modified on 2020/12/03 18:20:43

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Delirium prevention and prediction,Part 2

Acronym

Delirium prevention and prediction,Part 2

Scientific Title

Delirium prevention and prediction,Part 2

Scientific Title:Acronym

Delirium prevention and prediction,Part 2

Region

Japan


Condition

Condition

delirium

Classification by specialty

Psychiatry

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

We examine whether suvolexant is effective for the prevention of delirium.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Incidence of delirium as determined by the DSM-5.

Key secondary outcomes

1. Estimates of the probability of developing delirium
2. Change in inflammatory markers


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -but assessor(s) are blinded

Control

Placebo

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is considered as a block.

Blocking

YES

Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Medicine

Interventions/Control_1

suvolexant

Interventions/Control_2

placebo

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

65 years-old <=

Age-upper limit

90 years-old >

Gender

Male and Female

Key inclusion criteria

Patients newly admitted due to emergency, and able to take medicine orally

Key exclusion criteria

Patients who have an expected stay or life expectancy less than 2 night

Target sample size

78


Research contact person

Name of lead principal investigator

1st name Kotaro
Middle name
Last name Hatta

Organization

Juntendo University Nerima Hospital

Division name

Department of Psychiatry

Zip code

177-8521

Address

Takanodai 3-1-10, Nerima-ku, Tokyo 177-8521, Japan

TEL

+81-3-5923-3111

Email

khatta@juntendo.ac.jp


Public contact

Name of contact person

1st name Kotaro
Middle name
Last name Hatta

Organization

Juntendo University Nerima Hospital

Division name

Department of Psychiatry

Zip code

177-8521

Address

Takanodai 3-1-10, Nerima-ku, Tokyo 177-8521, Japan

TEL

+81-3-5923-3111

Homepage URL


Email

khatta@juntendo.ac.jp


Sponsor or person

Institute

Juntendo University

Institute

Department

Personal name



Funding Source

Organization

Japan Society for the Promotion of Science (Grant-in-Aid for Scientific Research C)

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

Nippon Medical School Musashikosugi Hospital
Hiroshima City Hospital
Tokyo Medical and Dental University
Kanazawa University Graduate School of Medical Science

Name of secondary funder(s)



IRB Contact (For public release)

Organization

IRB of Juntendo University Nerima Hospital

Address

Takanodai 3-1-10, Nerima-ku, Tokyo 177-8521, Japan

Tel

+81359233111

Email

khatta@juntendo.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

順天堂大学医学部附属練馬病院(東京都)
東京医科歯科大学病院(東京都)
日本医科大学附属武蔵小杉病院(神奈川県)
広島市立広島市民病院(広島県)


Other administrative information

Date of disclosure of the study information

2015 Year 02 Month 28 Day


Related information

URL releasing protocol

http://doi.org/10.4088/JCP.16m11194

Publication of results

Published


Result

URL related to results and publications

http://doi.org/10.4088/JCP.16m11194

Number of participants that the trial has enrolled

72

Results

We found that development of delirium occurred significantly less often among patients taking suvorexant than those taking placebo (0% [n/N=0/36] vs.17% [6/36], P=.025). Comparison by log-rank test also showed that development of delirium occurred significantly less often among patients taking suvorexant than those taking placebo (chi-square=6.46, P=.011). Analysis of variance revealed a tendency for main effect of treatment (F=3.79, P=.053) on Sleep-wake cycle disturbance score (item 1) of DRS-R98-J.

Results date posted

2020 Year 12 Month 03 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

Eligible patients were 65-89 years old, newly admitted due to emergency, and able to take medicine orally, and had an expected stay or life expectancy 48 h or more.

Participant flow

Seventy-two patients were randomly assigned using the sealed envelope method to receive suvorexant (15 mg/day; 36 patients) and placebo (36 patients) every night for three days.

Adverse events

There were no significant differences in adverse events.

Outcome measures

The primary outcome measure was incidence of delirium as determined by the DSM-5.

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2015 Year 01 Month 13 Day

Date of IRB

2015 Year 01 Month 13 Day

Anticipated trial start date

2015 Year 04 Month 01 Day

Last follow-up date

2016 Year 03 Month 03 Day

Date of closure to data entry

2016 Year 03 Month 10 Day

Date trial data considered complete

2016 Year 03 Month 10 Day

Date analysis concluded

2016 Year 03 Month 16 Day


Other

Other related information



Management information

Registered date

2014 Year 11 Month 13 Day

Last modified on

2020 Year 12 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018227


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name